Targeting the tumor mutanome for personalized vaccination therapy
Next generation sequencing enables identification of immunogenic tumor mutations
targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-
of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of
the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor
control, qualifying mutated epitopes as source for effective vaccines.
targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-
of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of
the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor
control, qualifying mutated epitopes as source for effective vaccines.
Next generation sequencing enables identification of immunogenic tumor mutations targetable by individualized vaccines. In the B16F10 melanoma system as pre-clinical proof-of-concept model, we found a total of 563 non-synonymous expressed somatic mutations. Of the mutations we tested, one third were immunogenic. Immunization conferred in vivo tumor control, qualifying mutated epitopes as source for effective vaccines.
Taylor & Francis Online